1
|
Huang Z, Li L, Cheng B, Li D. Small molecules targeting HDAC6 for cancer treatment: Current progress and novel strategies. Biomed Pharmacother 2024; 178:117218. [PMID: 39084081 DOI: 10.1016/j.biopha.2024.117218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2024] [Revised: 07/23/2024] [Accepted: 07/26/2024] [Indexed: 08/02/2024] Open
Abstract
Histone deacetylase 6 (HDAC6) plays a crucial role in the initiation and progression of various cancers, as its overexpression is linked to tumor growth, invasion, migration, survival, apoptosis, and angiogenesis. Therefore, HDAC6 has emerged as an attractive target for anticancer drug discovery in the past decade. However, the development of conventional HDAC6 inhibitors has been hampered by their limited clinical efficacy, acquired resistance, and inability to inhibit non-enzymatic functions of HDAC6. To overcome these challenges, new strategies, such as dual-acting inhibitors, targeted protein degradation (TPD) technologies (including PROTACs, HyT), are essential to enhance the anticancer activity of HDAC6 inhibitors. In this review, we focus on the recent advances in the design and development of HDAC6 modulators, including isoform-selective HDAC6 inhibitors, HDAC6-based dual-target inhibitors, and targeted protein degraders (PROTACs, HyT), from the perspectives of rational design, pharmacodynamics, pharmacokinetics, and clinical status. Finally, we discuss the challenges and future directions for HDAC6-based drug discovery for cancer therapy.
Collapse
Affiliation(s)
- Ziqian Huang
- Department of Pharmacy, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, PR China
| | - Ling Li
- The Eighth Affiliated Hospital Sun Yat-sen University, 3025 Shennan Middle Road, Shenzhen 518000, China.
| | - Binbin Cheng
- School of Medicine, Hubei Polytechnic University, Huangshi 435003, China.
| | - Deping Li
- Department of Pharmacy, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, PR China.
| |
Collapse
|
2
|
Deepthi A, Leena SS, Krishnan D. Update on thiopyran-fused heterocycle synthesis (2013-2024). Org Biomol Chem 2024; 22:5676-5717. [PMID: 38912843 DOI: 10.1039/d4ob00497c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/25/2024]
Abstract
Thiopyrans and their fused derivatives have significant synthetic relevance owing to their biological importance and occurrence in natural products. The current article provides an overview of synthetic strategies employed for the construction of thiopyran-fused heterocycles. In particular, this article discusses synthetic methods for the fusion of thiopyran with heterocycles such as indole, quinoline, pyrimidine, pyridine, thiophene, chromene, oxazole, pyrazole, pyran and furan and covers the literature from 2013 to 2024. The most common precursors for thiopyrano[2,3-b]indoles, thiopyranoquinolines and thiopyranothiazoles are indoline-2-thione, 2-mercaptoquinoline-3-carbaldehyde and thiazolidinone, respectively, and various reactions involving these are described in detail here. Asymmetric syntheses of thiopyranoindoles achieved using chiral catalysts based on thiourea, proline and metal complexes are also included. The biological activity associated with some compounds is also discussed.
Collapse
Affiliation(s)
- Ani Deepthi
- Department of Chemistry, University of Kerala, Kariavattom, Trivandrum - 695581, Kerala, India.
| | | | - Devika Krishnan
- Department of Chemistry, University of Kerala, Kariavattom, Trivandrum - 695581, Kerala, India.
| |
Collapse
|
3
|
Zhong LJ, Chen H, Shang X, Xiong BQ, Tang KW, Liu Y. Oxidant-Assisted Sulfonylation/Cyclization Cascade Synthesis of Alkylsulfonylated Oxindoles via the Insertion of SO 2. J Org Chem 2024; 89:5409-5422. [PMID: 38563439 DOI: 10.1021/acs.joc.3c02860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
An oxidant-assisted tandem sulfonylation/cyclization of electron-deficient alkenes with 4-alkyl-substituted Hantzsch esters and Na2S2O5 for the preparation of 3-alkylsulfonylated oxindoles under mild conditions in the absence of a photocatalyst and transition metal catalyst is established. The mechanism studies show that the alkyl radicals, which come from the cleavage of the C-C bond in 4-substituted Hantzsch esters under oxidant conditions, subsequently undergo the in situ insertion of sulfur dioxide to generate the crucial alkylsulfonyl radical intermediates. This three-component reaction provides an efficient and facile route for the construction of alkylsulfonylated oxindoles and avoids the use of highly toxic alkylsulfonyl chlorides or alkylsulfonyl hydrazines as alkylsulfonyl sources.
Collapse
Affiliation(s)
- Long-Jin Zhong
- Department of Chemistry and Chemical Engineering, Hunan Institute of Science and Technology, Yueyang 414006, China
| | - Hui Chen
- Department of Chemistry and Chemical Engineering, Hunan Institute of Science and Technology, Yueyang 414006, China
| | - Xuan Shang
- Department of Chemistry and Chemical Engineering, Hunan Institute of Science and Technology, Yueyang 414006, China
| | - Bi-Quan Xiong
- Department of Chemistry and Chemical Engineering, Hunan Institute of Science and Technology, Yueyang 414006, China
| | - Ke-Wen Tang
- Department of Chemistry and Chemical Engineering, Hunan Institute of Science and Technology, Yueyang 414006, China
| | - Yu Liu
- Department of Chemistry and Chemical Engineering, Hunan Institute of Science and Technology, Yueyang 414006, China
| |
Collapse
|
4
|
De Vita S, Meninno S, Capasso L, Colarusso E, Chini MG, Lauro G, Rinaldi R, De Cicco A, Sian V, Terracciano S, Nebbioso A, Lattanzi A, Bifulco G. 2-Substituted 1,5-benzothiazepine-based HDAC inhibitors exert anticancer activities on human solid and acute myeloid leukemia cell lines. Bioorg Med Chem 2023; 93:117444. [PMID: 37611334 DOI: 10.1016/j.bmc.2023.117444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 07/31/2023] [Accepted: 08/11/2023] [Indexed: 08/25/2023]
Abstract
Herein, we report the development of a new series of histone deacetylase inhibitors (HDACi) containing a 2-substituted 1,5-benzothiazepine scaffold. First, a virtual combinatorial library (∼1.6 × 103 items) was built according to a convenient synthetic route, and then it was submitted to molecular docking experiments on seven HDACs isoforms belonging to classes I and II. Integrated computational filters were used to select the most promising ones that were synthesized through an optimized approach, also amenable to generating both racemic and enantioenriched benzothiazepine-based derivatives. The obtained compounds showed potent HDAC inhibitory activity, especially those containing the sulphone moiety, endowed with IC50 in the nanomolar range. In addition, in vitro outcomes of our synthesized compounds demonstrated a cytotoxic effect on U937 and HCT116 cell lines and an arrest in the G2/M phase (13 ≤ IC50 ≤ 18 µM). Finally, Western blot analyses outlined the modulation of the histone acetyl markers such as H3K9/14, acetyl-tubulin, and the apoptotic indicator p21 in both cancer cell lines, disclosing a good HDAC inhibitor activity exerted by the designed items. Given the key role of HDACs in many cellular pathways, which makes these enzymes appealing and "hot" drug targets, our findings highlighted the importance of these 2-substituted 1,5-benzothiazepine-based compounds (both in the reduced and oxidized version) for the development of novel epidrugs.
Collapse
Affiliation(s)
- Simona De Vita
- Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy.
| | - Sara Meninno
- Department of Chemistry and Biology "A. Zambelli", University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy.
| | - Lucia Capasso
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Vico L. De Crecchio 7, 80138 Naples, Italy.
| | - Ester Colarusso
- Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy.
| | - Maria Giovanna Chini
- Department of Biosciences and Territory, University of Molise, Contrada Fonte Lappone, Pesche, Isernia 86090, Italy.
| | - Gianluigi Lauro
- Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy.
| | - Romolo Rinaldi
- Department of Chemistry and Biology "A. Zambelli", University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy.
| | - Annalisa De Cicco
- Department of Chemistry and Biology "A. Zambelli", University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy.
| | - Veronica Sian
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Vico L. De Crecchio 7, 80138 Naples, Italy.
| | - Stefania Terracciano
- Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy.
| | - Angela Nebbioso
- Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Vico L. De Crecchio 7, 80138 Naples, Italy.
| | - Alessandra Lattanzi
- Department of Chemistry and Biology "A. Zambelli", University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy.
| | - Giuseppe Bifulco
- Department of Pharmacy, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy.
| |
Collapse
|
5
|
Geurs S, Clarisse D, De Bosscher K, D'hooghe M. The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs. J Med Chem 2023. [PMID: 37276138 DOI: 10.1021/acs.jmedchem.3c00226] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Histone deacetylases (HDACs) are enzymes pursued as drug targets in various cancers and several non-oncological conditions, such as inflammation and neurodegenerative disorders. In the past decade, HDAC inhibitors (HDACi) have emerged as relevant pharmaceuticals, with many efforts devoted to the development of new representatives. However, the growing safety concerns regarding the established hydroxamic acid-based HDAC inhibitors tend to drive current research more toward the design of inhibitors bearing alternative zinc-binding groups (ZBGs). This Perspective presents an overview of all non-hydroxamic acid ZBGs that have been incorporated into the clinically approved prototypical HDACi, suberoylanilide hydroxamic acid (vorinostat). This provides the unique opportunity to compare the inhibition potential and biological effects of different ZBGs in a direct way, as the compounds selected for this Perspective differ only in their ZBG. To that end, different strategies used to select a ZBG, its properties, activity, and liabilities are discussed.
Collapse
Affiliation(s)
- Silke Geurs
- SynBioC Research Group, Department of Green Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium
- Translational Nuclear Receptor Research, VIB-UGent Center for Medical Biotechnology, Technologiepark-Zwijnaarde 75, B-9052 Ghent, Belgium
| | - Dorien Clarisse
- Translational Nuclear Receptor Research, VIB-UGent Center for Medical Biotechnology, Technologiepark-Zwijnaarde 75, B-9052 Ghent, Belgium
- Department of Biomolecular Medicine, Ghent University, Technologiepark-Zwijnaarde 75, B-9052 Ghent, Belgium
| | - Karolien De Bosscher
- Translational Nuclear Receptor Research, VIB-UGent Center for Medical Biotechnology, Technologiepark-Zwijnaarde 75, B-9052 Ghent, Belgium
- Department of Biomolecular Medicine, Ghent University, Technologiepark-Zwijnaarde 75, B-9052 Ghent, Belgium
| | - Matthias D'hooghe
- SynBioC Research Group, Department of Green Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium
| |
Collapse
|
6
|
Yang FF, Hu T, Liu JQ, Yu XQ, Ma LY. Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment. Eur J Med Chem 2022; 245:114920. [PMID: 36399875 DOI: 10.1016/j.ejmech.2022.114920] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Revised: 10/25/2022] [Accepted: 11/08/2022] [Indexed: 11/14/2022]
|
7
|
Geurs S, Clarisse D, Baele F, Franceus J, Desmet T, De Bosscher K, D'hooghe M. Identification of mercaptoacetamide-based HDAC6 inhibitors via a lean inhibitor strategy: screening, synthesis, and biological evaluation. Chem Commun (Camb) 2022; 58:6239-6242. [PMID: 35510683 DOI: 10.1039/d2cc01550a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Non-selective inhibition of different histone deacetylase enzymes by hydroxamic acid-based drugs causes severe side effects when used as a (long-term) cancer treatment. In this work, we searched for a potent zinc-binding group able to replace the contested hydroxamic acid by employing a lean inhibitor strategy. This instructed the synthesis of a set of HDAC6-selective inhibitors containing the more desirable mercaptoacetamide moiety. Biological evaluation of these new compounds showed an IC50 in the nanomolar range, dose-dependent HDAC6 inhibition in MM1.S cells and improved genotoxicity results, rendering these new inhibitors valuable hits for applications even beyond oncology.
Collapse
Affiliation(s)
- Silke Geurs
- SynBioC Research Group, Department of Green Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium. .,Translational Nuclear Receptor Research, VIB-UGent Center for Medical Biotechnology, Technologiepark-Zwijnaarde 75, FSVMII, Zwijnaarde, Belgium
| | - Dorien Clarisse
- Translational Nuclear Receptor Research, VIB-UGent Center for Medical Biotechnology, Technologiepark-Zwijnaarde 75, FSVMII, Zwijnaarde, Belgium.,Department of Biomolecular Medicine, Ghent University, Technologiepark-Zwijnaarde 75, FSVMII, Zwijnaarde, Belgium
| | - Freya Baele
- SynBioC Research Group, Department of Green Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium.
| | - Jorick Franceus
- Center for Synthetic Biology (CSB), Department of Biotechnology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium
| | - Tom Desmet
- Center for Synthetic Biology (CSB), Department of Biotechnology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium
| | - Karolien De Bosscher
- Translational Nuclear Receptor Research, VIB-UGent Center for Medical Biotechnology, Technologiepark-Zwijnaarde 75, FSVMII, Zwijnaarde, Belgium.,Department of Biomolecular Medicine, Ghent University, Technologiepark-Zwijnaarde 75, FSVMII, Zwijnaarde, Belgium
| | - Matthias D'hooghe
- SynBioC Research Group, Department of Green Chemistry and Technology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, B-9000 Ghent, Belgium.
| |
Collapse
|
8
|
Suzdalev KF, Vyalyh JV, Tkachev VV, Lysenko EA, Burov ON, Lisovin AV, Kletskii ME, Kurbatov SV. Lithium-Promoted Cycloaddition of Indole-2,3-dienolates and Carbon Disulfide as a One-Pot Route to Thiopyrano[4,3- b]indole-3(5 H)-thiones. J Org Chem 2021; 86:11698-11707. [PMID: 34338514 DOI: 10.1021/acs.joc.1c01200] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A new approach for the annulation of a thiopyrane ring to an indole core under mild conditions was developed. Treating 2-methyl-3-acylindoles with lithium diisopropyl amide leads to the elimination of a proton from the 2-methyl group. The lithium indole-2,3-dienolates obtained were found to react with CS2 to give the corresponding thiopyrano[4,3-b]indole-3(5H)-thiones. The mechanism represents a stepwise addition through ion-pair formation, according to PCM/B3LYP/6-311++G**, PBE1PBE/6-311++G**, and MP2//HF/6-311++G** quantum chemical calculations. AIM calculations revealed the essential role of the Li atom at all stages of the process.
Collapse
Affiliation(s)
| | - Julia V Vyalyh
- Department of Chemistry, Southern Federal University, Rostov-on-Don 344090, Russia
| | - Valery V Tkachev
- Institute of Problems of Chemical Physics, Russian Academy of Sciences, Chernogolovka 142432, Russia
| | - Ekaterina A Lysenko
- Department of Chemistry, Southern Federal University, Rostov-on-Don 344090, Russia
| | - Oleg N Burov
- Department of Chemistry, Southern Federal University, Rostov-on-Don 344090, Russia
| | - Anton V Lisovin
- Department of Chemistry, Southern Federal University, Rostov-on-Don 344090, Russia
| | - Mikhail E Kletskii
- Department of Chemistry, Southern Federal University, Rostov-on-Don 344090, Russia
| | - Sergey V Kurbatov
- Department of Chemistry, Southern Federal University, Rostov-on-Don 344090, Russia
| |
Collapse
|
9
|
Pulya S, Amin SA, Adhikari N, Biswas S, Jha T, Ghosh B. HDAC6 as privileged target in drug discovery: A perspective. Pharmacol Res 2020; 163:105274. [PMID: 33171304 DOI: 10.1016/j.phrs.2020.105274] [Citation(s) in RCA: 124] [Impact Index Per Article: 31.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2020] [Revised: 10/15/2020] [Accepted: 10/25/2020] [Indexed: 12/25/2022]
Abstract
HDAC6, a class IIB HDAC isoenzyme, stands unique in its structural and physiological functions. Besides histone modification, largely due to its cytoplasmic localization, HDAC6 also targets several non-histone proteins including Hsp90, α-tubulin, cortactin, HSF1, etc. Thus, it is one of the key regulators of different physiological and pathological disease conditions. HDAC6 is involved in different signaling pathways associated with several neurological disorders, various cancers at early and advanced stage, rare diseases and immunological conditions. Therefore, targeting HDAC6 has been found to be effective for various therapeutic purposes in recent years. Though several HDAC6 inhibitors (HDAC6is) have been developed till date, only two ACY-1215 (ricolinostat) and ACY-241 (citarinostat) are in the clinical trials. A lot of work is still needed to pinpoint strictly selective as well as potent HDAC6i. Considering the recent crystal structure of HDAC6, novel HDAC6is of significant therapeutic value can be designed. Notably, the canonical pharmacophore features of HDAC6is consist of a zinc binding group (ZBG), a linker function and a cap group. Significant modifications of cap function may lead to achieve better selectivity of the inhibitors. This review details the study about the structural biology of HDAC6, the physiological and pathological role of HDAC6 in several disease states and the detailed structure-activity relationships (SARs) of the known HDAC6is. This detailed review will provide key insights to design novel and highly effective HDAC6i in the future.
Collapse
Affiliation(s)
- Sravani Pulya
- Epigenetic Research Laboratory, Department of Pharmacy, BITS-Pilani, Hyderabad Campus, Shamirpet, Hyderabad 500078, India
| | - Sk Abdul Amin
- Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, P. O. Box 17020, Jadavpur University, Kolkata 700032, India
| | - Nilanjan Adhikari
- Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, P. O. Box 17020, Jadavpur University, Kolkata 700032, India
| | - Swati Biswas
- Epigenetic Research Laboratory, Department of Pharmacy, BITS-Pilani, Hyderabad Campus, Shamirpet, Hyderabad 500078, India
| | - Tarun Jha
- Natural Science Laboratory, Division of Medicinal and Pharmaceutical Chemistry, Department of Pharmaceutical Technology, P. O. Box 17020, Jadavpur University, Kolkata 700032, India.
| | - Balaram Ghosh
- Epigenetic Research Laboratory, Department of Pharmacy, BITS-Pilani, Hyderabad Campus, Shamirpet, Hyderabad 500078, India.
| |
Collapse
|
10
|
Depetter Y, Geurs S, Franceus J, Knez D, Desmet T, De Bosscher K, De Wever O, Gobec S, D'hooghe M. Synthesis of Indoline‐Based Benzhydroxamic Acids as Potential HDAC6 Inhibitors. ChemistrySelect 2019. [DOI: 10.1002/slct.201902042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Yves Depetter
- SynBioC Research GroupDepartment of Green Chemistry and TechnologyFaculty of Bioscience EngineeringGhent University Coupure Links 653 B-9000 Ghent Belgium
| | - Silke Geurs
- SynBioC Research GroupDepartment of Green Chemistry and TechnologyFaculty of Bioscience EngineeringGhent University Coupure Links 653 B-9000 Ghent Belgium
| | - Jorick Franceus
- Centre for Synthetic Biology (CSB)Department of BiotechnologyFaculty of Bioscience EngineeringGhent University Coupure Links 653 B-9000 Ghent Belgium
| | - Damijan Knez
- Department of Pharmaceutical ChemistryFaculty of PharmacyUniversity of Ljubljana Aškerčeva 7 1000 Ljubljana Slovenia
| | - Tom Desmet
- Centre for Synthetic Biology (CSB)Department of BiotechnologyFaculty of Bioscience EngineeringGhent University Coupure Links 653 B-9000 Ghent Belgium
| | - Karolien De Bosscher
- Translational Nuclear Receptor Research labVIB Department of Medical Protein ResearchDepartment of Biomolecular MedicineGhent University Albert Baertsoenkaai 3 B-9000 Ghent Belgium
| | - Olivier De Wever
- Laboratory of Experimental Cancer ResearchDepartment of Human Structure and RepairGhent University Corneel Heymanslaan 10 B-9000 Ghent Belgium
| | - Stanislav Gobec
- Department of Pharmaceutical ChemistryFaculty of PharmacyUniversity of Ljubljana Aškerčeva 7 1000 Ljubljana Slovenia
| | - Matthias D'hooghe
- SynBioC Research GroupDepartment of Green Chemistry and TechnologyFaculty of Bioscience EngineeringGhent University Coupure Links 653 B-9000 Ghent Belgium
| |
Collapse
|
11
|
Géraldy M, Morgen M, Sehr P, Steimbach RR, Moi D, Ridinger J, Oehme I, Witt O, Malz M, Nogueira MS, Koch O, Gunkel N, Miller AK. Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated. J Med Chem 2019; 62:4426-4443. [PMID: 30964290 DOI: 10.1021/acs.jmedchem.8b01936] [Citation(s) in RCA: 52] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The discovery of isozyme-selective histone deacetylase (HDAC) inhibitors is critical for understanding the biological functions of individual HDACs and for validating HDACs as drug targets. The isozyme HDAC10 contributes to chemotherapy resistance and has recently been described to be a polyamine deacetylase, but no studies toward selective HDAC10 inhibitors have been published. Using two complementary assays, we found Tubastatin A, an HDAC6 inhibitor, to potently bind HDAC10. We synthesized Tubastatin A derivatives and found that a basic amine in the cap group was required for strong HDAC10 binding. HDAC10 inhibitors mimicked knockdown by causing dose-dependent accumulation of acidic vesicles in a neuroblastoma cell line. Furthermore, docking into human HDAC10 homology models indicated that a hydrogen bond between a cap group nitrogen and the gatekeeper residue Glu272 was responsible for potent HDAC10 binding. Taken together, our data provide an optimal platform for the development of HDAC10-selective inhibitors, as exemplified with the Tubastatin A scaffold.
Collapse
Affiliation(s)
| | | | - Peter Sehr
- Chemical Biology Core Facility , European Molecular Biology Laboratory , 69117 Heidelberg , Germany
| | | | | | - Johannes Ridinger
- Biosciences Faculty , University of Heidelberg , 69120 Heidelberg , Germany.,Hopp Children's Cancer Center Heidelberg (KiTZ) , 69120 Heidelberg , Germany.,Department of Pediatric Oncology, Hematology and Immunology , University Hospital Heidelberg , 69120 Heidelberg , Germany
| | - Ina Oehme
- Hopp Children's Cancer Center Heidelberg (KiTZ) , 69120 Heidelberg , Germany.,German Cancer Consortium (DKTK) , 69120 Heidelberg , Germany
| | - Olaf Witt
- Hopp Children's Cancer Center Heidelberg (KiTZ) , 69120 Heidelberg , Germany.,Department of Pediatric Oncology, Hematology and Immunology , University Hospital Heidelberg , 69120 Heidelberg , Germany.,German Cancer Consortium (DKTK) , 69120 Heidelberg , Germany
| | | | - Mauro S Nogueira
- Faculty of Chemistry and Chemical Biology , TU Dortmund University , 44227 Dortmund , Germany
| | - Oliver Koch
- Faculty of Chemistry and Chemical Biology , TU Dortmund University , 44227 Dortmund , Germany
| | - Nikolas Gunkel
- German Cancer Consortium (DKTK) , 69120 Heidelberg , Germany
| | - Aubry K Miller
- German Cancer Consortium (DKTK) , 69120 Heidelberg , Germany
| |
Collapse
|
12
|
Depetter Y, Geurs S, De Vreese R, Goethals S, Vandoorn E, Laevens A, Steenbrugge J, Meyer E, de Tullio P, Bracke M, D'hooghe M, De Wever O. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models. Int J Cancer 2019; 145:735-747. [DOI: 10.1002/ijc.32169] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2018] [Revised: 12/14/2018] [Accepted: 01/22/2019] [Indexed: 02/03/2023]
Affiliation(s)
- Yves Depetter
- SynBioC Research Group, Department of Green Chemistry and Technology, Faculty of Bioscience Engineering; Ghent University; Ghent Belgium
- Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Faculty of Medicine and Health Sciences; Ghent University; Ghent Belgium
- Cancer Research Institute Ghent (CRIG); Ghent Belgium
| | - Silke Geurs
- SynBioC Research Group, Department of Green Chemistry and Technology, Faculty of Bioscience Engineering; Ghent University; Ghent Belgium
| | - Rob De Vreese
- SynBioC Research Group, Department of Green Chemistry and Technology, Faculty of Bioscience Engineering; Ghent University; Ghent Belgium
| | - Sophie Goethals
- Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Faculty of Medicine and Health Sciences; Ghent University; Ghent Belgium
| | - Elien Vandoorn
- Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Faculty of Medicine and Health Sciences; Ghent University; Ghent Belgium
| | - Alien Laevens
- Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Faculty of Medicine and Health Sciences; Ghent University; Ghent Belgium
| | - Jonas Steenbrugge
- Laboratory of Biochemistry, Department of Pharmacology, Toxicology and Biochemistry, Faculty of Veterinary Medicine; Ghent University; Merelbeke Belgium
| | - Evelyne Meyer
- Cancer Research Institute Ghent (CRIG); Ghent Belgium
- Laboratory of Biochemistry, Department of Pharmacology, Toxicology and Biochemistry, Faculty of Veterinary Medicine; Ghent University; Merelbeke Belgium
| | - Pascal de Tullio
- Center for Interdisciplinary Research on Medicines (CIRM), Metabolomics Group; Université de Liège; Liège Belgium
| | - Marc Bracke
- Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Faculty of Medicine and Health Sciences; Ghent University; Ghent Belgium
- Cancer Research Institute Ghent (CRIG); Ghent Belgium
| | - Matthias D'hooghe
- SynBioC Research Group, Department of Green Chemistry and Technology, Faculty of Bioscience Engineering; Ghent University; Ghent Belgium
| | - Olivier De Wever
- Laboratory of Experimental Cancer Research, Department of Human Structure and Repair, Faculty of Medicine and Health Sciences; Ghent University; Ghent Belgium
- Cancer Research Institute Ghent (CRIG); Ghent Belgium
| |
Collapse
|
13
|
Yang F, Zhao N, Ge D, Chen Y. Next-generation of selective histone deacetylase inhibitors. RSC Adv 2019; 9:19571-19583. [PMID: 35519364 PMCID: PMC9065321 DOI: 10.1039/c9ra02985k] [Citation(s) in RCA: 74] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2019] [Accepted: 06/17/2019] [Indexed: 12/13/2022] Open
Abstract
Histone deacetylases (HDACs) are clinically validated epigenetic drug targets for cancer treatment. HDACs inhibitors (HDACis) have been successfully applied against a series of cancers. First-generation inhibitors are mainly pan-HDACis that target multiple isoforms which might lead to serious side effects. At present, the next-generation HDACis are mainly focused on being class- or isoform-selective which can provide improved risk–benefit profiles compared to non-selective inhibitors. Because of the rapid development in next-generation HDACis, it is necessary to have an updated and state-of-the-art overview. Here, we summarize the strategies and achievements of the selective HDACis. Histone deacetylases (HDACs) are clinically validated epigenetic drug targets for cancer treatment.![]()
Collapse
Affiliation(s)
- Feifei Yang
- School of Biological Science and Technology
- University of Jinan
- Jinan
- China
- Shanghai Key Laboratory of Regulatory Biology
| | - Na Zhao
- School of Biological Science and Technology
- University of Jinan
- Jinan
- China
| | - Di Ge
- School of Biological Science and Technology
- University of Jinan
- Jinan
- China
| | - Yihua Chen
- Shanghai Key Laboratory of Regulatory Biology
- The Institute of Biomedical Sciences and School of Life Sciences
- East China Normal University
- Shanghai
- China
| |
Collapse
|
14
|
Depetter Y, Geurs S, Vanden Bussche F, De Vreese R, Franceus J, Desmet T, De Wever O, D'hooghe M. Assessment of the trifluoromethyl ketone functionality as an alternative zinc-binding group for selective HDAC6 inhibition. MEDCHEMCOMM 2018; 9:1011-1016. [PMID: 30108990 PMCID: PMC6072519 DOI: 10.1039/c8md00107c] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/26/2018] [Accepted: 05/04/2018] [Indexed: 01/23/2023]
Abstract
Recent studies point towards the possible disadvantages of using hydroxamic acid-based zinc-binding groups in HDAC inhibitors due to e.g. mutagenicity issues. In this work, we elaborated on our previously developed Tubathian series, a class of highly selective thiaheterocyclic HDAC6 inhibitors, by replacing the benzohydroxamic acid function by an alternative zinc chelator, i.e., an aromatic trifluoromethyl ketone. Unfortunately, these compounds showed a reduced potency to inhibit HDAC6 as compared to their hydroxamic acid counterparts. In agreement, the most active trifluoromethyl ketone was unable to influence the growth of SK-OV-3 ovarian cancer cells nor to alter the acetylation status of tubulin and histone H3. These data suggest that replacement of the zinc-binding hydroxamic acid function with a trifluoromethyl ketone zinc-binding moiety within reported benzohydroxamic HDAC6 inhibitors should not be considered as a standard strategy in HDAC inhibitor development.
Collapse
Affiliation(s)
- Yves Depetter
- SynBioC Research Group , Department of Green Chemistry and Technology , Faculty of Bioscience Engineering , Ghent University , Coupure Links 653 , B-9000 Ghent , Belgium .
- Laboratory of Experimental Cancer Research , Department of Radiation Oncology and Experimental Cancer Research , Ghent University , Corneel Heymanslaan 10 , B-9000 Ghent , Belgium
- Cancer Research Institute Ghent (CRIG) , Ghent , Belgium
| | - Silke Geurs
- SynBioC Research Group , Department of Green Chemistry and Technology , Faculty of Bioscience Engineering , Ghent University , Coupure Links 653 , B-9000 Ghent , Belgium .
| | - Flore Vanden Bussche
- SynBioC Research Group , Department of Green Chemistry and Technology , Faculty of Bioscience Engineering , Ghent University , Coupure Links 653 , B-9000 Ghent , Belgium .
| | - Rob De Vreese
- SynBioC Research Group , Department of Green Chemistry and Technology , Faculty of Bioscience Engineering , Ghent University , Coupure Links 653 , B-9000 Ghent , Belgium .
| | - Jorick Franceus
- Centre for Synthetic Biology (CSB) , Department of Biotechnology , Faculty of Bioscience Engineering , Ghent University , Coupure Links 653 , B-9000 Ghent , Belgium
| | - Tom Desmet
- Centre for Synthetic Biology (CSB) , Department of Biotechnology , Faculty of Bioscience Engineering , Ghent University , Coupure Links 653 , B-9000 Ghent , Belgium
| | - Olivier De Wever
- Laboratory of Experimental Cancer Research , Department of Radiation Oncology and Experimental Cancer Research , Ghent University , Corneel Heymanslaan 10 , B-9000 Ghent , Belgium
- Cancer Research Institute Ghent (CRIG) , Ghent , Belgium
| | - Matthias D'hooghe
- SynBioC Research Group , Department of Green Chemistry and Technology , Faculty of Bioscience Engineering , Ghent University , Coupure Links 653 , B-9000 Ghent , Belgium .
| |
Collapse
|
15
|
Liu J, Qian C, Zhu Y, Cai J, He Y, Li J, Wang T, Zhu H, Li Z, Li W, Hu L. Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold. Bioorg Med Chem 2017; 26:747-757. [PMID: 29317150 DOI: 10.1016/j.bmc.2017.12.041] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2017] [Revised: 12/18/2017] [Accepted: 12/24/2017] [Indexed: 12/31/2022]
Abstract
Both histone deacetylase (HDAC) and fibroblast growth factor receptor (FGFR) are important targets for cancer therapy. Although combining dual HDAC pharmacophore with tyrosine kinase inhibitors (TKIs) had achieved a successful progress, dual HDAC/FGFR1 inhibitors haven't been reported yet. Herein, we designed a series of hybrids bearing 1H-indazol-3-amine and benzohydroxamic acids scaffold with scaffold hopping and molecular hybridization strategies. Among them, compound 7j showed the most potent inhibitory activity against HDAC6 with IC50 of 34 nM and exhibited the great inhibitory activities against a human breast cancer cell line MCF-7 with IC50 of 9 μM in vitro. Meanwhile, the compound also exhibited moderate FGFR1 inhibitory activities. This study provides new tool compounds for further exploration of dual HDAC/FGFR1 inhibition.
Collapse
Affiliation(s)
- Jian Liu
- School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China; Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing 210023, Jiangsu, China
| | - Chengbo Qian
- School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China
| | - Yehua Zhu
- School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China
| | - Jianguo Cai
- School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China
| | - Yufang He
- School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China
| | - Jie Li
- Pharmacy, Nanjing General Hospital, 305 Zhongshan East Road, Nanjing 210002, China
| | - Tianlin Wang
- School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China
| | - Haohao Zhu
- School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China
| | - Zhi Li
- School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China
| | - Wei Li
- School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China; Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing 210023, Jiangsu, China.
| | - Lihong Hu
- School of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing 210023, China; Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Nanjing 210023, Jiangsu, China; Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, Stake Key Laboratory Cultivation Base for TCM Quality and Efficacy, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China
| |
Collapse
|
16
|
Lernoux M, Schnekenburger M, Dicato M, Diederich M. Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways. Pharmacol Res 2017; 129:337-356. [PMID: 29133216 DOI: 10.1016/j.phrs.2017.11.004] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Revised: 10/02/2017] [Accepted: 11/06/2017] [Indexed: 12/20/2022]
Abstract
Alterations of the epigenetic machinery, affecting multiple biological functions, represent a major hallmark enabling the development of tumors. Among epigenetic regulatory proteins, histone deacetylase (HDAC)6 has emerged as an interesting potential therapeutic target towards a variety of diseases including cancer. Accordingly, this isoenzyme regulates many vital cellular regulatory processes and pathways essential to physiological homeostasis, as well as tumor multistep transformation involving initiation, promotion, progression and metastasis. In this review, we will consequently discuss the critical implications of HDAC6 in distinct mechanisms relevant to physiological and cancerous conditions, as well as the anticancer properties of synthetic, natural and natural-derived compounds through the modulation of HDAC6-related pathways.
Collapse
Affiliation(s)
- Manon Lernoux
- Laboratory of Molecular and Cellular Biology of Cancer, Kirchberg Hospital, 9, Edward Steichen Street, L-2540 Luxembourg, Luxembourg
| | - Michael Schnekenburger
- Laboratory of Molecular and Cellular Biology of Cancer, Kirchberg Hospital, 9, Edward Steichen Street, L-2540 Luxembourg, Luxembourg
| | - Mario Dicato
- Laboratory of Molecular and Cellular Biology of Cancer, Kirchberg Hospital, 9, Edward Steichen Street, L-2540 Luxembourg, Luxembourg
| | - Marc Diederich
- Department of Pharmacy, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, 08826, South Korea.
| |
Collapse
|
17
|
Recent advances in the discovery of potent and selective HDAC6 inhibitors. Eur J Med Chem 2017; 143:1406-1418. [PMID: 29133060 DOI: 10.1016/j.ejmech.2017.10.040] [Citation(s) in RCA: 99] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2017] [Revised: 10/14/2017] [Accepted: 10/14/2017] [Indexed: 01/07/2023]
Abstract
Histone deacetylase HDAC6, a member of the class IIb HDAC family, is unique among HDAC enzymes in having two active catalytic domains, and has unique physiological function. In addition to the modification of histone, HDAC6 targets specific substrates including α-tubulin and HSP90, and are involved in protein trafficking and degradation, cell shape and migration. Selective HDAC6 inhibitors are an emerging class of pharmaceuticals due to the involvement of HDAC6 in different pathways related to neurodegenerative diseases, cancer, and immunology. Therefore, extensive investigations have been made in the discovery of selective HDAC6 inhibitors. Based on their different zinc binding groups (ZBGs), in this review, HDAC6 inhibitors are grouped as hydroxamic acids, a sulfur containing ZBG based derivatives and other ZBG-derived compounds, and their enzymatic inhibitory activity, selectivity and other biological activities are introduced and summarized.
Collapse
|
18
|
Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors. Eur J Med Chem 2017; 135:174-195. [DOI: 10.1016/j.ejmech.2017.04.013] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 04/03/2017] [Accepted: 04/07/2017] [Indexed: 02/08/2023]
|
19
|
Abstract
Aim: The recurring resistance of the malaria parasite to many drugs compels the design of innovative chemical entities in antimalarial research. Pan-histone deacetylase inhibitors (pan-HDACis) have recently been presented in the literature as powerful novel antimalarials, although their application is hampered due to toxic side effects. This drawback might be neutralized by the deployment of isoform-selective HDACis. Results: In this study, 42 thiaheterocyclic benzohydroxamic acids, 17 of them being potent and selective hHDAC6 inhibitors, were tested to investigate a possible correlation between hHDAC6 inhibition and antiplasmodial activity. Conclusion: Four hHDAC6 inhibitors showed submicromolar potency against both a chloroquine-sensitive and a chloroquine-resistant strain of Plasmodium falciparum with high selectivity indices, pointing to the relevance of exploring hHDAC6 inhibitors as potential new antiplasmodial agents.
Collapse
|
20
|
De Vreese R, Galle L, Depetter Y, Franceus J, Desmet T, Van Hecke K, Benoy V, Van Den Bosch L, D'hooghe M. Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold. Chemistry 2016; 23:128-136. [DOI: 10.1002/chem.201604167] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2016] [Indexed: 01/12/2023]
Affiliation(s)
- Rob De Vreese
- SynBioC Research Group; Faculty of Bioscience Engineering; Ghent University; Coupure Links 653 9000 Ghent Belgium
| | - Lisa Galle
- SynBioC Research Group; Faculty of Bioscience Engineering; Ghent University; Coupure Links 653 9000 Ghent Belgium
| | - Yves Depetter
- SynBioC Research Group; Faculty of Bioscience Engineering; Ghent University; Coupure Links 653 9000 Ghent Belgium
| | - Jorick Franceus
- Centre for Industrial Biotechnology and Biocatalysis; Faculty of Bioscience Engineering; Ghent University; Coupure Links 653 9000 Ghent Belgium
| | - Tom Desmet
- Centre for Industrial Biotechnology and Biocatalysis; Faculty of Bioscience Engineering; Ghent University; Coupure Links 653 9000 Ghent Belgium
| | - Kristof Van Hecke
- XStruct, Department of Inorganic and Physical Chemistry; Faculty of Sciences; Ghent University; Krijgslaan 281-S3 9000 Ghent Belgium
| | - Veronick Benoy
- University of Leuven; Department of Neurosciences, Experimental Neurology, VIB-Vesalius Research Center, Laboratory of Neurobiology; 3000 Leuven Belgium
| | - Ludo Van Den Bosch
- University of Leuven; Department of Neurosciences, Experimental Neurology, VIB-Vesalius Research Center, Laboratory of Neurobiology; 3000 Leuven Belgium
| | - Matthias D'hooghe
- SynBioC Research Group; Faculty of Bioscience Engineering; Ghent University; Coupure Links 653 9000 Ghent Belgium
| |
Collapse
|
21
|
Yoo J, Kim SJ, Son D, Seo H, Baek SY, Maeng CY, Lee C, Kim IS, Jung YH, Lee SM, Park HJ. Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity. Eur J Med Chem 2016; 116:126-135. [DOI: 10.1016/j.ejmech.2016.03.046] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Revised: 03/16/2016] [Accepted: 03/17/2016] [Indexed: 02/06/2023]
|
22
|
Abaee MS, Forghani S, Mojtahedi MM, Harms K. Facile one-pot synthesis of novel dicyanoanilines fused to tetrahydro-4H-thiopyran-4-one ring via Et3N/H2O catalyzed pseudo four-component reaction. J Sulphur Chem 2016. [DOI: 10.1080/17415993.2016.1182170] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- M. Saeed Abaee
- Department of Organic Chemistry and Natural Products, Chemistry and Chemical Engineering Research Center of Iran, Tehran, Iran
| | - Soodabeh Forghani
- Department of Organic Chemistry and Natural Products, Chemistry and Chemical Engineering Research Center of Iran, Tehran, Iran
| | - Mohammad M. Mojtahedi
- Department of Organic Chemistry and Natural Products, Chemistry and Chemical Engineering Research Center of Iran, Tehran, Iran
| | - Klaus Harms
- Fachbereich Chemie der Philipps-Universitaet Marburg, Marburg, Germany
| |
Collapse
|
23
|
Diedrich D, Hamacher A, Gertzen CGW, Alves Avelar LA, Reiss GJ, Kurz T, Gohlke H, Kassack MU, Hansen FK. Rational design and diversity-oriented synthesis of peptoid-based selective HDAC6 inhibitors. Chem Commun (Camb) 2016; 52:3219-22. [DOI: 10.1039/c5cc10301k] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
A mini library of selective HDAC6 inhibitors with peptoid-based cap groups was synthesized using an efficient multicomponent approach.
Collapse
Affiliation(s)
- D. Diedrich
- Institut für Pharmazeutische und Medizinische Chemie
- Heinrich-Heine-Universität Düsseldorf
- 40225 Düsseldorf
- Germany
| | - A. Hamacher
- Institut für Pharmazeutische und Medizinische Chemie
- Heinrich-Heine-Universität Düsseldorf
- 40225 Düsseldorf
- Germany
| | - C. G. W. Gertzen
- Institut für Pharmazeutische und Medizinische Chemie
- Heinrich-Heine-Universität Düsseldorf
- 40225 Düsseldorf
- Germany
| | - L. A. Alves Avelar
- Institut für Pharmazeutische und Medizinische Chemie
- Heinrich-Heine-Universität Düsseldorf
- 40225 Düsseldorf
- Germany
| | - G. J. Reiss
- Institut für Anorganische Chemie und Strukturchemie
- Heinrich-Heine-Universität Düsseldorf
- 40225 Düsseldorf
- Germany
| | - T. Kurz
- Institut für Pharmazeutische und Medizinische Chemie
- Heinrich-Heine-Universität Düsseldorf
- 40225 Düsseldorf
- Germany
| | - H. Gohlke
- Institut für Pharmazeutische und Medizinische Chemie
- Heinrich-Heine-Universität Düsseldorf
- 40225 Düsseldorf
- Germany
| | - M. U. Kassack
- Institut für Pharmazeutische und Medizinische Chemie
- Heinrich-Heine-Universität Düsseldorf
- 40225 Düsseldorf
- Germany
| | - F. K. Hansen
- Institut für Pharmazeutische und Medizinische Chemie
- Heinrich-Heine-Universität Düsseldorf
- 40225 Düsseldorf
- Germany
| |
Collapse
|
24
|
De Vreese R, Depetter Y, Verhaeghe T, Desmet T, Benoy V, Haeck W, Van Den Bosch L, D′hooghe M. Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors. Org Biomol Chem 2016; 14:2537-49. [DOI: 10.1039/c5ob02625c] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Hydroxamic acids 2c, 2d and 3i-m represent valuable lead structures in the pursuit of novel potent and selective HDAC6 inhibitors.
Collapse
Affiliation(s)
- Rob De Vreese
- SynBioC Research Group
- Faculty of Bioscience Engineering
- Ghent University
- B-9000 Ghent
- Belgium
| | - Yves Depetter
- SynBioC Research Group
- Faculty of Bioscience Engineering
- Ghent University
- B-9000 Ghent
- Belgium
| | - Tom Verhaeghe
- Centre for Industrial Biotechnology and Biocatalysis
- Faculty of Bioscience Engineering
- Ghent University
- B-9000 Ghent
- Belgium
| | - Tom Desmet
- Centre for Industrial Biotechnology and Biocatalysis
- Faculty of Bioscience Engineering
- Ghent University
- B-9000 Ghent
- Belgium
| | - Veronick Benoy
- Laboratory of Neurobiology and Vesalius Research Center (VIB)
- Research Institute for Neuroscience and Disease (LIND)
- KU Leuven
- Belgium
| | - Wanda Haeck
- Laboratory of Neurobiology and Vesalius Research Center (VIB)
- Research Institute for Neuroscience and Disease (LIND)
- KU Leuven
- Belgium
| | - Ludo Van Den Bosch
- Laboratory of Neurobiology and Vesalius Research Center (VIB)
- Research Institute for Neuroscience and Disease (LIND)
- KU Leuven
- Belgium
| | - Matthias D′hooghe
- SynBioC Research Group
- Faculty of Bioscience Engineering
- Ghent University
- B-9000 Ghent
- Belgium
| |
Collapse
|
25
|
Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, Califano A, Silva J. HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Res 2015; 17:149. [PMID: 26643555 PMCID: PMC4672555 DOI: 10.1186/s13058-015-0658-0] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2015] [Accepted: 11/25/2015] [Indexed: 01/13/2023] Open
Abstract
INTRODUCTION Inflammatory breast cancer (IBC) is the most lethal form of breast cancers with a 5-year survival rate of only 40 %. Despite its lethality, IBC remains poorly understood which has greatly limited its therapeutic management. We thus decided to utilize an integrative functional genomic strategy to identify the Achilles' heel of IBC cells. METHODS We have pioneered the development of genetic tools as well as experimental and analytical strategies to perform RNAi-based loss-of-function studies at a genome-wide level. Importantly, we and others have demonstrated that these functional screens are able to identify essential functions linked to certain cancer phenotypes. Thus, we decided to use this approach to identify IBC specific sensitivities. RESULTS We identified and validated HDAC6 as a functionally necessary gene to maintain IBC cell viability, while being non-essential for other breast cancer subtypes. Importantly, small molecule inhibitors for HDAC6 already exist and are in clinical trials for other tumor types. We thus demonstrated that Ricolinostat (ACY1215), a leading HDAC6 inhibitor, efficiently controls IBC cell proliferation both in vitro and in vivo. Critically, functional HDAC6 dependency is not associated with genomic alterations at its locus and thus represents a non-oncogene addiction. Despite HDAC6 not being overexpressed, we found that its activity is significantly higher in IBC compared to non-IBC cells, suggesting a possible rationale supporting the observed dependency. CONCLUSION Our finding that IBC cells are sensitive to HDAC6 inhibition provides a foundation to rapidly develop novel, efficient, and well-tolerated targeted therapy strategies for IBC patients.
Collapse
Affiliation(s)
- Preeti Putcha
- Herbert Irving Comprehensive Cancer Center, Columbia University, 1130 St. Nicholas Avenue, New York, NY, 10032, USA
| | - Jiyang Yu
- Department of Biomedical Informatics, Department of Systems Biology, Center for Computational Biology and Bioinformatics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, 10032, USA
| | - Ruth Rodriguez-Barrueco
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-6574, USA.,Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Laura Saucedo-Cuevas
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-6574, USA
| | - Patricia Villagrasa
- Department of Pathology, Columbia University Medical Center, 630 West 168th Street, New York, NY, 10032, USA
| | - Eva Murga-Penas
- Department of Pathology, Columbia University Medical Center, 630 West 168th Street, New York, NY, 10032, USA
| | - Steven N Quayle
- Acetylon Pharmaceuticals, Inc., 70 Fargo St, Suite 205, Boston, MA, 02210, USA
| | - Min Yang
- Acetylon Pharmaceuticals, Inc., 70 Fargo St, Suite 205, Boston, MA, 02210, USA
| | - Veronica Castro
- Department of Pathology, Columbia University Medical Center, 630 West 168th Street, New York, NY, 10032, USA
| | - David Llobet-Navas
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-6574, USA
| | - Daniel Birnbaum
- Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France
| | - Pascal Finetti
- Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France
| | - Wendy A Woodward
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - François Bertucci
- Centre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France
| | - Mary L Alpaugh
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
| | - Andrea Califano
- Department of Biomedical Informatics, Department of Systems Biology, Center for Computational Biology and Bioinformatics, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, 10032, USA. .,Department of Biochemistry and Molecular Biophysics, Institute for Cancer Genetics, Columbia University, New York, NY, 10032, USA. .,Herbert Irving Comprehensive Cancer Center, Columbia University, 1130 St. Nicholas Avenue, New York, NY, 10032, USA.
| | - Jose Silva
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029-6574, USA.
| |
Collapse
|
26
|
De Vreese R, Van Steen N, Verhaeghe T, Desmet T, Bougarne N, De Bosscher K, Benoy V, Haeck W, Van Den Bosch L, D'hooghe M. Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors. Chem Commun (Camb) 2015; 51:9868-71. [DOI: 10.1039/c5cc03295d] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
A small library of 3-[(4-hydroxycarbamoylphenyl)aminomethyl]benzothiophenes was prepared, leading to the identification of three representatives as potent and selective HDAC6 inhibitors.
Collapse
|
27
|
Thaler F, Mercurio C. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next. ChemMedChem 2014; 9:523-6. [PMID: 24730063 DOI: 10.1002/cmdc.201300413] [Citation(s) in RCA: 73] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Histone deacetylases (HDACs) are widely studied targets for the treatment of cancer and other diseases. Up to now, over twenty HDAC inhibitors have entered clinical studies and two of them have already reached the market, namely the hydroxamic acid derivative SAHA (vorinostat, Zolinza) and the cyclic depsipeptide FK228 (romidepsin, Istodax) that have been approved for the treatment of cutaneous T-cell lymphoma (CTCL). A common aspect of the first HDAC inhibitors is the absence of any particular selectivity towards specific isozymes. Some of molecules resulted to be “pan”-HDAC inhibitors, while others are class I selective. In the meantime, the knowledge of HDAC biology has continuously progressed. Key advances in the structural biology of various isozymes, reliable molecular homology models as well as suitable biological assays have provided new tools for drug discovery activities. This Minireview aims at surveying these recent developments as well as the design, synthesis and biological characterization of isoform-selective derivatives.
Collapse
|
28
|
Krämer OH, Mahboobi S, Sellmer A. Drugging the HDAC6–HSP90 interplay in malignant cells. Trends Pharmacol Sci 2014; 35:501-9. [DOI: 10.1016/j.tips.2014.08.001] [Citation(s) in RCA: 97] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2014] [Revised: 08/07/2014] [Accepted: 08/08/2014] [Indexed: 12/22/2022]
|